EUVIMEDEUVIMED entdecken
Kommentar

Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent

Neal J Weinreb, Ozlem Goker-Alpan

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.19336 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA Network Open, 2023. Verfasst von Neal J Weinreb und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, University of Miami Miller School of Medicine, Boca Raton, Florida. Hauptthemen laut MEDLINE: Ambroxol, Gaucher Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zhan and colleagues 1 describe hematologic, visceral, and chemical biomarker outcomes in 28 Chinese individuals (17 children and 11 adults) with Gaucher disease (GD) who were treated with ambroxol for a mean (SD) of 2.6 (1.7) years. 1 Two children had early-onset neuronopathic disease (GD3) with genotypes p. L483P/L483P and L483P/D448H, and 1 child had intermediate disease (GD2-3) with genotype R202X/R535C.Among the 15 patients classified as having nonneuronopathic GD (GD1), 1 was homozygous for L483P and 7 had a single L483P allele.No individual had even a single neuroprotective N409S GBA1 variant, whose presence is confined to European-derived populations.Seven of 11 patients who had anemia before starting ambroxol treatment achieved normal hemoglobin concentrations.Substantial decreases in hepatomegaly were observed in 6 of 8 evaluable patients.In patients treated for at least 2 years, plasma glucosylsphingosine and chitotriosidase concentrations decreased by 34.1% and 43.1%, respectively, from markedly elevated pretreatment levels.However, responses in thrombocytopenic and splenomegalic patients showed only small incremental increases in platelet count.Only 2 of 21 patients attained platelet counts greater than 120 cells ×10 3 /μL.Platelet counts failed to improve or decreased in 9 patients.Spleen volumes decreased in 4 of 8 evaluable patients, but the spleen volume decreased to less than 8 multiples of normal in only 1 patient.The best responses were observed in younger patients with GBA1 genotypes known to be associated with milder GD manifestations.There were no major safety issues.In most high-income countries, symptomatic patients with GD1 usually have recourse to several safe and effective treatments, either intravenous enzyme replenishment therapy (ERT) or oral substrate restriction therapy (SRT).However, ERT and SRT are both very expensive.Additionally, each treatment category is imperfect and associated with unmet therapeutic needs or potential adverse effects.ERT is limited by uneven tissue distribution, occasional infusion reactions, exclusion from the central nervous system by the blood brain barrier, and, sometimes, poor venous access.Eliglustat SRT is restricted by exclusions, including children, pregnant and breastfeeding women, patients with advanced cardiac or liver disease, and those using incompatible concurrent medications that are metabolized by cytochrome P450 2d6 or 3A.Miglustat, which is approved as a second-line agent, causes frequent and severe gastrointestinal adverse events and, possibly, peripheral neuropathy. 2 Thus, there is an opportunity to develop new therapies.Of the more than 500 known pathogenic GBA1 variant alleles, many, including those that are rarely encountered by Western geneticists, are transcribed and translated by endoplasmic reticulum (ER)-bound polyribosomes into misfolded variant glucocerebrosidase (GCase) protein.On translocation into the ER, the misfolded GCase is conformationally unable to undergo N-glycosylation and/or binding to endogenous chaperones, steps that are essential for trafficking to the Golgi and, thence, to the lysosome.Rather, the variant enzyme is ubiquitinated and designated for ER-associated degradation in the proteasome, a compensatory mechanism termed the unfolded protein response, which eventually is overwhelmed, resulting in ER retention and aggregation of the misfolded protein.This process converges with lysosomal dysfunction attributable to storage of poorly soluble glucosylceramide and secondary related substrates, aggregation of additional lysosome-processed proteins such as α-synuclein, leakage of cathepsins and other lysosomal hydrolases, disruption of the vital autophagy-lysosomal pathway, mitochondrial degradation (mitophagy) with progressive cellular energy deficits, plasma membrane instability, extrusion of +

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmbroxolGaucher DiseaseHumansGlucosylceramidaseMutation

Substanzen

AmbroxolGlucosylceramidase

Autor:innen und Institutionen

  • Department of Human Genetics, University of Miami Miller School of Medicine, Boca Raton, Florida.
  • Lysosomal and Rare Diseases Research and Treatment Center, Fairfax, Virginia.

Zitieren

APA

Weinreb, N. J., & Goker-Alpan, O. (2023). Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.19336

Vancouver

Weinreb NJ, Goker-Alpan O. Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.19336

BibTeX
@article{Weinreb2023,
  author = {Weinreb, Neal J and Goker-Alpan, Ozlem},
  title = {Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.19336}
}
Kostenlos starten →